Cytomegalovirus retinitis

disease
On this page

Also known as Cytomegaloviral RetinitisCytomegalovirus caused retinitisRetinitis, Cytomegaloviral

Summary

Cytomegalovirus retinitis (MONDO:0000878) is a disease and 62 clinical trials. Top therapeutic interventions include foscarnet, ganciclovir, and cidofovir anhydrous. A subtype of retinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 62

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecytomegalovirus retinitis
Mondo IDMONDO:0000878
EFOEFO:1001302
MeSHD017726
DOIDDOID:0080160
ICD-11315493536
NCITC50521
SNOMED CT22455005
UMLSC0206178
MedGen61532
GARD0009531
Is cancer (heuristic)no

Also known as: Cytomegaloviral Retinitis · Cytomegalovirus caused retinitis · Cytomegalovirus retinitis · cytomegalovirus retinitis · Retinitis, Cytomegaloviral

Disease family

This is a subtype of retinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinitiscytomegalovirus retinitis

Related subtypes (4): histoplasmosis retinitis, acute retinal necrosis syndrome, optic papillitis, retinal vasculitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
FomivirsenApproved (phase 4)
GanciclovirApproved (phase 4)
FoscarnetPhase 3 (in late-stage trials)
SargramostimPhase 3 (in late-stage trials)
ValganciclovirPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fomivirsen Sodium.

Clinical trials & evidence

Clinical trials

Clinical trials: 62.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified29
PHASE211
PHASE39
PHASE18
PHASE43
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00000894PHASE4COMPLETEDComparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
NCT00002125PHASE4COMPLETEDA Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)
NCT01866397PHASE4COMPLETEDPharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
NCT00000118PHASE3COMPLETEDGanciclovir Implant Study for Cytomegalovirus Retinitis
NCT00000134PHASE3COMPLETEDStudies of the Ocular Complications of AIDS (SOCA)–Cytomegalovirus Retinitis Retreatment Trial (CRRT)
NCT00000135PHASE2/PHASE3COMPLETEDStudies of the Ocular Complications of AIDS (SOCA)–Monoclonal Antibody CMV Retinitis Trial (MACRT)
NCT00000136PHASE3COMPLETEDStudies of the Ocular Complications of AIDS (SOCA)–Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
NCT00000143PHASE3COMPLETEDStudies of Ocular Complications of AIDS (SOCA)–Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
NCT00000688PHASE3COMPLETEDA Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
NCT00000698PHASE3COMPLETEDA Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis
NCT00002070PHASE3COMPLETEDPhase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
NCT00002377PHASE3COMPLETEDA Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
NCT00017784PHASE3UNKNOWNValganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
NCT00000691PHASE2COMPLETEDA Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
NCT00000697PHASE2WITHDRAWNA Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir
NCT00000766PHASE2COMPLETEDCMV Retinitis Retreatment Trial
NCT00000836PHASE2COMPLETEDA Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)
NCT00001034PHASE2COMPLETEDThe Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV
NCT00001061PHASE2COMPLETEDComparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
NCT00002156PHASE2COMPLETEDA Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
NCT00002169PHASE2COMPLETEDA Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
NCT00002356PHASE2COMPLETEDThe Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
NCT00002437PHASE2COMPLETEDThe Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT00004794PHASE2COMPLETEDPhase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
NCT00000668PHASE1COMPLETEDA Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir
NCT00000673PHASE1COMPLETEDA Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy
NCT00000726PHASE1COMPLETEDFoscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome
NCT00000881PHASE1WITHDRAWNA Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
NCT00000970PHASE1COMPLETEDA Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir
NCT00001062PHASE1COMPLETEDA Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
NCT00002016PHASE1COMPLETEDA Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
NCT00002321PHASE1COMPLETEDA Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
NCT05911503EARLY_PHASE1RECRUITINGClinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
NCT00000168Not specifiedCOMPLETEDLongitudinal Study of Ocular Complications of AIDS (LSOCA)
NCT00000665Not specifiedCOMPLETEDStudies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
NCT00000693Not specifiedCOMPLETEDSuppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
NCT00000799Not specifiedCOMPLETEDHPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
NCT00000905Not specifiedCOMPLETEDA Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
NCT00000989Not specifiedCOMPLETEDThe Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS
NCT00001611Not specifiedCOMPLETEDImmune Activity Against CVM Retinitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
FOSCARNET448
GANCICLOVIR428
CIDOFOVIR ANHYDROUS418
PROBENECID45
FOMIVIRSEN SODIUM44
VALGANCICLOVIR43
SARGRAMOSTIM42
ACYCLOVIR41
HUMAN IMMUNOGLOBULIN G41
INTERFERON BETA-1B41
NELFINAVIR MESYLATE41
SEVIRUMAB24
CHEMBL36544201